GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Gallbladder and Pancreas/Optimal timing for LAMS removal after EUS-guided drainage of PFC
51

Optimal timing for LAMS removal after EUS-guided drainage of PFC

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2025

The optimal timing for lumen-apposing metal stent (LAMS) removal after EUS-guided drainage of pancreatic fluid collections (PFCs) does not necessarily depend on a fixed timeline, such as early removal within 3–4 weeks. A systematic review and meta-analysis of 8 studies involving 1820 patients found no significant difference in adverse events (AEs) between early and late stent removal. The pooled risk ratio for AEs was 1.03, indicating comparable safety outcomes regardless of removal timing. Additionally, a sensitivity analysis using a strict 4-week cut-off confirmed these findings.

Prolonged stent placement has been associated with complications like bleeding, buried stents, and infection, but early removal does not appear to reduce these risks. The study suggests that removal timing should be guided by clinical judgment rather than a universal early-removal policy. Factors such as patient stability, imaging findings, and individual circumstances should dictate the decision, supporting a case-by-case approach rather than adhering to a rigid timeline.

Related Q&A

52

Portal versus peripheral circulating tumor cells in PDAC

The study you referenced investigates the differences between portal and peripheral circulating tumor cells (CTCs) in pancreatic ductal adenocarcinoma (PDAC) and their prognostic value. Here’s a detailed breakdown...

53

Risk of Pancreatic Cancer in Patients With Chronic Pancreatitis

Patients with chronic pancreatitis face a significantly increased risk of developing pancreatic cancer compared to individuals without pancreatitis. According to the systematic review and meta-analysis, chronic pancreatitis is...

54

Risk factor analysis for survival prediction in severe acute pancreatitis

Risk factor analysis for survival prediction in severe acute pancreatitis (SAP) focuses on identifying key clinical and biochemical parameters that influence patient outcomes. In the specific context of...

55

Biomarker testing in biliary tract cancer

Biomarker testing in biliary tract cancer (BTC) has emerged as a critical tool for guiding precision therapy, improving treatment outcomes, and understanding the molecular landscape of this heterogeneous...

56

Acalculus Biliary Pain and Acalculus Cholecystitis

Both acalculus biliary pain and acalculus cholecystitis are conditions associated with the gallbladder but differ in their presentation, underlying mechanisms, and clinical significance. Below is a detailed breakdown:...

57

SBRT versus chemoradiation after induction chemotherapy in locally advanced pancreatic cancer

The study described compares the outcomes of Stereotactic Body Radiation Therapy (SBRT) versus Conventional Chemoradiation (CRT) following induction chemotherapy in patients with Locally Advanced Pancreatic Cancer (LAPC) and...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer